Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDFWART and Docetaxel for Recurrent Ovarian Cancer
NCT02083536Phase 1Withdrawn
- Sponsor
- University of Miami
- Start
- May 2014
- Primary completion
- May 2019
01
Overview
Phase 1, open-label, single-arm trial in ovarian cancer, sponsored by University of Miami. Primary endpoints: Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability at 3 years and Recommended Phase II Dose of LDFWART at 3 years. Planned start May 2014; status: withdrawn.
02
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02083536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083536.